Mar 12, 2018
Dr. SriniVas Sadda discusses development of macular atrophy in an analysis of HARBOR Study which investigated treatment of wet AMD using 0.5 mg and 2.0 mg of Ranibizumab dosing.
Full reference of the discussed article:
Sadda, S. R., Tuomi, L. L., Ding, B., Fung, A. E., & Hopkins, J. J. (2018). Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Ophthalmology. doi:10.1016/j.ophtha.2017.12.026